Claritev Corporation (NYSE: CTEV) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -17.33 | Insider Own | 23.65% | Shs Outstand | 17.05M | Perf Week | 11.32% |
| Market Cap | 414.09M | Forward P/E | - | EPS next Y | -13.87 | Insider Trans | 2.41% | Shs Float | 7.28M | Perf Month | -25.58% |
| Enterprise Value | 5.00B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 5.79% | Perf Quarter | -2.57% |
| Income | -288.00M | P/S | 0.42 | EPS this Y | 8.09% | Inst Trans | - | Short Ratio | 6.74 | Perf Half Y | -10.57% |
| Sales | 980.00M | P/B | - | EPS next Y | 12.89% | ROA | -5.92% | Short Interest | 986.97K | Perf YTD | -43.18% |
| Book/sh | -13.73 | P/C | 19.72 | EPS next 5Y | - | ROE | 205.84% | 52W High | 80.51 -67.21% | Perf Year | -39.08% |
| Cash/sh | 1.23 | P/FCF | - | EPS past 3/5Y | - | ROIC | 0.78% | 52W Low | 12.50 111.22% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | 9.66 | Sales past 3/5Y | -3.68% 0.57% | Gross Margin | 61.06% | Volatility | 8.59% 8.77% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 5.10 | EPS Y/Y TTM | 83.00% | Oper. Margin | 4.29% | ATR (14) | 2.42 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.28 | Sales Y/Y TTM | 5.26% | Profit Margin | -29.27% | RSI (14) | 41.95 | Recom | 2.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.28 | EPS Q/Q | -28.57% | SMA20 | -10.65% | Beta | 2.18 | Target Price | 38.80 |
| Payout | 0.00% | Debt/Eq | 54.01 | Sales Q/Q | 6.06% | SMA50 | -13.86% | Rel Volume | 0.38 | Prev Close | 24.29 |
| Employees | 3,000 | LT Debt/Eq | -27.62 | Earnings | Aug 07 | SMA200 | -22.32% | Avg Volume | 149.12K | Price | 26.40 |
| IPO Date | Apr 03, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -7.94% 3.51% | Net Debt/EBITDA | 8.87 | Volume | 55,917 | Change | 8.69% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-21-26 | Reiterated | Canaccord Genuity | Buy | $37 |
| Jun-03-26 | Reiterated | Piper Sandler | Overweight | $90 → $61 |
| Apr-24-26 | Initiated | Barclays | Overweight | $28 |
| Feb-24-26 | Reiterated | Guggenheim | Buy | $38 |
| Feb-24-26 | Reiterated | Wells Fargo | Equal Weight | $33 → $30 |
| Jan-08-26 | Initiated | Wells Fargo | Equal Weight | $33 |
| Oct-22-25 | Upgrade | Citigroup | Neutral → Buy | |
| Oct-21-25 | Upgrade | Citigroup | Neutral → Buy | |
| May-29-25 | Upgrade | Piper Sandler | Neutral → Overweight |
Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure discounted rates through contracts with healthcare providers and provide outsourced administration for these provider networks. Claritev also specializes in payment and revenue integrity, identifying and removing erroneous or unwarranted charges processed during claims, while simultaneously working to identify, recover, and safeguard underpaid premium amounts. Furthermore, their data and decision science offerings encompass a range of solutions that apply modern data science methodologies—including descriptive, predictive, and prescriptive analytics—to refine benefit plan structures, aid strategic decision-making, enhance patient clinical results, and ultimately lower overall healthcare costs. The company also handles business-to-business healthcare payment processing and other related services. Their diverse clientele includes major national and regional insurance carriers, Blue Cross and Blue Shield organizations, various provider-sponsored and independent health plans, third-party administrators (TPAs), self-insured health plans, property and casualty insurers, bill review firms, and other entities involved in the claims settlement process. Established in 1980 and headquartered in New York, New York, Claritev Corporation was previously known as MultiPlan Corporation before officially adopting its current name in February 2025.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 980 | 965 | 931 | 962 | 1,080 | 1,118 | 938 | 983 | 1,041 | |
| Cost of Goods Sold Incl. D&A | 381 | 699 | 239 | 235 | 204 | 175 | 319 | 150 | 149 | |
| Gross Profit | 599 | 267 | 691 | 726 | 876 | 942 | 619 | 833 | 891 | |
| Selling, General and Administrative Excl. Other | 207 | 222 | 160 | 136 | 132 | 151 | 356 | 75 | 78 | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other Operating Expense | 349 | 0 | 1,921 | 428 | 1,106 | 405 | 395 | 390 | 386 | |
| Operating Income | 43 | 45 | -1,390 | 162 | -363 | 386 | -132 | 368 | 428 | |
| Interest Expense | 398 | 400 | 326 | 333 | 303 | 267 | 336 | 376 | 383 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 27 | -18 | -54 | 64 | 105 | 17 | -79 | 19 | 0 | |
| Net Income Before Taxes | -329 | -373 | -1,771 | -107 | -561 | 135 | -547 | 11 | 44 | |
| Income Taxes | -41 | -89 | -125 | -15 | 12 | 33 | -26 | 1 | 8 | |
| Consolidated Net Income | -288 | -284 | -1,646 | -92 | -573 | 102 | -521 | 10 | 36 | |
| Net Income From Continuing Operations | -288 | -284 | -1,646 | -92 | -573 | 102 | -521 | 10 | 36 | |
| Net Income | -288 | -284 | -1,646 | -92 | -573 | 102 | -521 | 10 | 36 | |
| EPS (Recurring) | -17.33 | -17.30 | -101.92 | -5.69 | -35.87 | 6.40 | -44.23 | 0.35 | 1.32 | |
| EPS (Basic, Before Extraordinaries) | -17.33 | -17.30 | -101.92 | -5.69 | -35.87 | 6.40 | -44.23 | 0.35 | 1.32 | |
| EPS (Diluted) | -17.33 | -17.30 | -101.92 | -5.69 | -35.87 | 6.40 | -44.23 | 0.35 | 1.32 | |
| EBITDA | 518 | 475 | -1,008 | 652 | 158 | 815 | 192 | 786 | 814 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.46 | 0.71 | — | — | — | — | — | — | — | |
| Gross Margin | 61.12 | 27.67 | 74.22 | 75.47 | 81.11 | 84.26 | 65.99 | 84.74 | 85.59 | |
| Operating Margin | 4.39 | 4.66 | -149.30 | 16.84 | -33.61 | 34.53 | -14.07 | 37.44 | 41.11 | |
| Net Margin | -29.39 | -29.43 | -176.80 | -9.56 | -53.06 | 9.12 | -55.54 | 1.02 | 3.46 | |
| Shares Outstanding | 17 | 16 | 16 | 16 | 16 | 16 | 12 | 28 | 28 | |
| Market Capitalization | 449 | 684 | — | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Carol Nutter | SVP, Chief People Officer | Jun 09 '26 | Buy | 28.41 | 875 | 24,856 | 46,941 | Jun 10 |
| Prince John Michael | Director | May 19 '26 | Buy | 16.00 | 10,000 | 160,000 | 31,662 | May 19 |
| Dalton Travis | Pres., CEO & Executive Chair | May 18 '26 | Buy | 12.36 | 20,920 | 258,638 | 45,872 | May 19 |
| Kim Michael | EVP, Chief Digital Officer | May 18 '26 | Buy | 16.65 | 3,000 | 49,950 | 185,878 | May 19 |
| Garis Douglas Michael | EVP&CFO | Mar 16 '26 | Buy | 17.69 | 1,300 | 22,997 | 206,152 | Mar 16 |
| Kim Michael | EVP, Chief Digital Officer | Mar 12 '26 | Buy | 16.50 | 15,000 | 247,500 | 182,878 | Mar 16 |
| O'Neil Tara | SVP, General Counsel | Mar 02 '26 | Buy | 12.99 | 750 | 9,743 | 27,199 | Mar 02 |
| Dalton Travis | Pres., CEO & Executive Chair | Feb 27 '26 | Buy | 13.00 | 15,380 | 199,928 | 24,952 | Mar 02 |
| Kim Michael | EVP, Chief Digital Officer | Feb 27 '26 | Buy | 14.30 | 30,000 | 428,955 | 137,973 | Mar 02 |
| Dalton Travis | Pres., CEO & Executive Chair | Nov 20 '25 | Buy | 47.23 | 5,290 | 249,842 | 9,572 | Nov 20 |
| Mintz William B. | SVP, Chief Strategy Officer | Nov 17 '25 | Buy | 38.00 | 916 | 34,808 | 65,325 | Nov 19 |
| Kim Michael | EVP, Chief Digital Officer | Nov 17 '25 | Buy | 38.25 | 9,600 | 367,199 | 105,529 | Nov 18 |
| O'Neil Tara | SVP, General Counsel | Nov 17 '25 | Buy | 38.84 | 625 | 24,273 | 25,028 | Nov 18 |
| H&F Corporate Investors VIII, Ltd. | 10% Owner | Nov 12 '25 | Sale | 48.67 | 1,500,000 | 73,001,249 | 8,932 | Nov 14 |
| Dalton Travis | Pres., CEO & Executive Chair | Aug 11 '25 | Buy | 58.30 | 3,982 | 232,158 | 4,282 | Aug 12 |